Business
Sun Pharma licenses LIB drug for $3.7 billion market
The Hindu BusinessLine··28 Sept
Sun Pharma signed a global licensing pact with LIB Therapeutics for cholesterol drug lerodalcibep outside the US and China. The company said the deal covers a $3.7-billion PCSK9 market growing at 38 percent CAGR. Europe alone accounted for $2.9 billion of that market in MAT Q2 2026. Managing Director Kirti W Ganorkar said once-monthly dosing simplifies treatment.
Prism
What It Means For You
- Sun Pharma gains exclusive rights to lerodalcibep outside the United States and China.
- The firm will pursue regulatory approvals in licensed territories that are not yet cleared.
- Patients in those markets may see a once-monthly PCSK9 option if approvals follow.
What's Happening
- LIB Therapeutics' drug has European Commission authorisation under the brand Lyrokaul.
- In the US it is FDA-approved as Lerochol.
- Sun Pharma framed the pact as a step to expand its Innovative Medicines cardiovascular portfolio.
How large the PCSK9 market is
- Sun Pharma put the non-US, non-China PCSK9 market at $3.7 billion with 38 percent CAGR.
- Europe contributed $2.9 billion of that market in MAT Q2 2026.
- The company highlighted small-volume injection and six-month ambient storage as product features.
all-news
